Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) Gross Margin: 2018-2024

Historic Gross Margin for Akebia Therapeutics (AKBA) over the last 7 years, with Dec 2024 value amounting to 60.56%.

  • Akebia Therapeutics' Gross Margin rose 2187.00% to 84.03% in Q3 2025 from the same period last year, while for Sep 2025 it was 78.99%, marking a year-over-year decrease of 43798.00%. This contributed to the annual value of 60.56% for FY2024, which is 70205.00% up from last year.
  • Latest data reveals that Akebia Therapeutics reported Gross Margin of 60.56% as of FY2024, which was up 109.44% from -641.49% recorded in FY2023.
  • In the past 5 years, Akebia Therapeutics' Gross Margin registered a high of 70.74% during FY2022, and its lowest value of -641.49% during FY2023.
  • In the last 3 years, Akebia Therapeutics' Gross Margin had a median value of 60.56% in 2024 and averaged -170.06%.
  • Its Gross Margin has fluctuated over the past 5 years, first surged by 135,274bps in 2020, then crashed by 71,223bps in 2023.
  • Over the past 5 years, Akebia Therapeutics' Gross Margin (Yearly) stood at -0.62% in 2020, then soared by 2,943bps to 28.81% in 2021, then surged by 4,193bps to 70.74% in 2022, then plummeted by 71,223bps to -641.49% in 2023, then soared by 70,205bps to 60.56% in 2024.